Drug intelligence / Profile preview

SSH1 siRNA

Development stage
Unknown
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

SSH1 siRNA is a small interfering RNA designed to silence the expression of Slingshot Homolog 1 (SSH1), a member of the Slingshot family of protein phosphatases. SSH1 plays a pivotal role in regulating the actin cytoskeleton by dephosphorylating and activating cofilin, an actin-binding protein that promotes filament severing and depolymerization. This SSH1-cofilin axis is essential for various cellular processes, including cell migration, cytokinesis, and neuronal development. In the context of oncology, SSH1 is often overexpressed in aggressive tumors, where it facilitates cell invasion and metastasis, making it a target for potential antineoplastic therapies. Furthermore, SSH1 has been implicated in neurodegenerative conditions such as Alzheimer's disease, where its activity contributes to the formation of cofilin-actin rods and tau-mediated synaptic dysfunction. While SSH1 siRNA is a widely utilized research tool for investigating these biological pathways in vitro and in vivo, it has not yet advanced into formal clinical trials as a therapeutic product.

Other names
Slingshot-1 siRNASlingshot1 siRNASlingshot 1 siRNASSH1L siRNASSH-1L siRNASSH 1L siRNAsiRNA targeting SSH1
02

Targets

SSH1 (Slingshot phosphatase 1)

Beyond the preview

Go deeper on SSH1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSH1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call